A range of approaches have been developed to block the TGF-β signalling cascade, with key clinical leads in cancer treatment including anti-TGF-β antibodies, anti-TGF-β receptor antibodies, and small molecular inhibitors of TGFR-linked kinases [261]. Here, TGFB1 is linked to cancer.